Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuevolution, Merck License Agreement

Published: Friday, February 21, 2014
Last Updated: Friday, February 21, 2014
Bookmark and Share
Agreement for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.

Under terms of the agreement, Merck will gain exclusive rights for the further development and commercialization of the compounds. This is the second agreement between Nuevolution and Merck. Nuevolution will receive an undisclosed upfront payment and milestone payments for certain preclinical, clinical and agreed upon commercial milestones.  In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products.  Further financial details were not disclosed.

With this agreement, Nuevolution delivers on its new strategy to transform from a technology platform biotech company to a lead compound development company, providing novel products to improve future health treatments for patients.

Nuevolution applies its Chemetics® platform to identify small molecule drug candidates for therapeutically important targets. Chemetics® uses proprietary innovative DNA labelling to allow small molecule screening at an unprecedented scale for lead discovery. The technology allows efficient screening of billions of molecules against biological targets. Nuevolution has patented its Chemetics® technology and holds a strong validated patent portfolio within the technology field. In its existing collaborations and internal pipeline development, Nuevolution has successfully addressed several challenging targets including protein-protein interactions by the identification of drug-like small molecules.

“This agreement is the first pre-clinical compound out-licensing agreement for Nuevolution. It marks the immediate realization of our chosen strategy to both offer access to our technology as well as out-license leads identified by the use of the Chemetics® platform” said Alex Gouliaev, CEO of Nuevolution A/S and continued, “We are very pleased to see that the compounds will be developed further by Merck.”

Stig Løkke Pedersen, Chairman of Nuevolution A/S adds: “looking at our deal track record, Chemetics® has provided us with a commercially proven lead discovery engine. The out-licensing of compounds represents the best future source of sustainable growth for the company. It is very encouraging to see existing partnerships develop into long term relationships.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Wednesday, September 21, 2011
Nuevolution Enters Lead Discovery Collaboration in the Field of Epigenetic Disorders
A consortium has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.
Thursday, October 07, 2010
Scientific News
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Simplifying Gene Testing Access for Ovarian Cancer Patients
Simplifying access to gene testing for women with ovarian cancer improves treatment choices and could save lives.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
New Skin Cancer Drugs with Surprising Powers
Inserm team synthesizes and developed new drugs for melanoma.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!